ArticleFrontiers in oncology2025
CORO1A: a pan-cancer prognosis, diagnostic and immune biomarker based on breast cancer validation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Intratumoral PD-1Medical oncology (Northwood, London, England) · 2026Article
- High expression of CD74 is associated with poor prognosis and tumor immune infiltration in Acute Myeloid Leukemia.Discover oncology · 2026Article
- Construction of a risk model based on folate metabolism-related genes to predict prognosis and immunological characteristics of stomach adenocarcinoma.Discover oncology · 2026Article
- Article
- The Ki-67 proliferation index in tertiary lymphoid structures as a predictor of survival outcomes in patients with resectable non-small cell lung cancer.BMC cancer · 2026Article
- CLTC expression in oral squamous cell carcinoma: insights into prognostic value and immune microenvironment modulation.World journal of surgical oncology · 2026Article
- Preoperative systemic inflammatory markers (SII, PLR, MRR) as potential indicators of axillary lymph node metastasis in early-stage breast cancer.Discover oncology · 2026Article
- Article
- Ferroptosis-related gene EPAS1 suppresses breast cancer progression by inhibiting M2 macrophage polarization.Discover oncology · 2026Article
- The cytoskeletal regulator Coronin-1A plays a multidirectional role in glioblastoma stemness.Scientific reports · 2026Article
- Identification of serum 5'tRF-Val as a promising non-invasive biomarker for early detection of esophageal cancer.Scientific reports · 2026Article
- A prognostic exosome-related mRNAs risk signature correlates with the immune microenvironment in breast cancer.Discover oncology · 2026Article
- TRIM11 is upregulated in esophageal cancer and promotes tumor progression through modulation of the β-catenin signaling pathway.Functional & integrative genomics · 2026Article
- Emerging roles for SNRPB2 in governing the cell cycle and steering tumor immune modulation in breast cancer.Molecular biology reports · 2026Article
- The role of alternative splicing in gastric cancer.Biology direct · 2026Review
- An exosome-related gene signature predicts prognosis, immune suppression, and therapeutic sensitivity in luminal breast cancer.Discover oncology · 2026Article
- S1PR4 connects cancer pain to pan-cancer mechanisms and reveals prognosis, immune infiltration and therapeutic potential.Discover oncology · 2026Article
- Bioinformatic analysis and cellular functional assays uncover the role of NXPH4 in breast cancer.Discover oncology · 2026Article
- Study of the prognostic value of the systemic immune-inflammation index combined with the triglyceride-glucose index in coronary heart disease: a retrospective study based on the MIMIC database.BMC cardiovascular disorders · 2026Article
- Survival prognosis and influencing factors in elderly patients with stage I-III breast cancer.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: CORO1A, a constituent of the Coronins family, is a conserved protein throughout evolution that interacts with actin within the cellular environment besides being involved in various malignancy development. Methods: A comprehensive analysis examining the discrepancies in expression levels, survival outcomes, immune cell infiltration (ICI), and enrichment profiles was performed. The expression of CORO1A in breast cancer tissues was verified by immunohistochemistry, WB and RT-qPCR experiments. The effects of different expression levels of CORO1A on the growth and metastasis of breast cancer cell lines were verified by CCK-8, colony formation, Trasnwell and cell scratch experiments. Results: The findings revealed a heightened expression of CORO1A in the 66.7% of tumor types (22/33), CORO1A consistently demonstrates high diagnostic potential and variable prognostic significance across cancers. In particular, its diagnostic value in SKCM reaches as high as 98%, with a prognostic hazard ratio of 0.77. CORO1A often characterized by hypomethylation of its promoter region, which correlates with the ICI level. Enrichment analysis highlights the critical contribution of CORO1A in B cell receptor pathways and other immune-linked processes, CORO1A may have multiple potential roles in B-cell receptor pathways, involving aspects such as signal transduction regulation, cytoskeletal remodeling and migration, as well as interactions with other immune molecules. exerting a substantial influence on patient prognosis. CORO1A is highly expressed in breast cancer tissues. Breast cancer patients with high expression of CORO1A have a good prognosis. CORO1A knockdown inhibits the growth and metastasis of breast cancer cells, while overexpression is the opposite. Therefore, due to its high diagnostic sensitivity and prognostic value demonstrated in various cancers, CORO1A holds promise as a candidate molecule for novel targeted therapies. Discussion: CORO1A, as a promising research target, has demonstrated significant and specific capabilities in predicting disease prognosis, analyzing immune responses, and exploring therapeutic approaches for different types of tumors, further highlighting the necessity for in-depth research on it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.